{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gates EWJ"],"funding":["Natural Sciences and Engineering Research Council of Canada","Canadian Institutes of Health Research"],"pagination":["1634"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9960274"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(4)"],"pubmed_abstract":["Factor XIIIa (FXIIIa) is a transglutaminase of major therapeutic interest for the development of anticoagulants due to its essential role in the blood coagulation cascade. While numerous FXIIIa inhibitors have been reported, they failed to reach clinical evaluation due to their lack of metabolic stability and low selectivity over transglutaminase 2 (TG2). Furthermore, the chemical tools available for the study of FXIIIa activity and localization are extremely limited. To combat these shortcomings, we designed, synthesised, and evaluated a library of 21 novel FXIIIa inhibitors. Electrophilic warheads, linker lengths, and hydrophobic units were varied on small molecule and peptidic scaffolds to optimize isozyme selectivity and potency. A previously reported FXIIIa inhibitor was then adapted "],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase."],"pmcid":["PMC9960274"],"funding_grant_id":["PJT-153089","PJT-162100","RGPIN-2019-05893"],"pubmed_authors":["Kaartinen MT","Shad S","Keillor JW","Mansour K","Ebrahimi Samani S","Gates EWJ"],"additional_accession":[]},"is_claimable":false,"name":"Peptidic Inhibitors and a Fluorescent Probe for the Selective Inhibition and Labelling of Factor XIIIa Transglutaminase.","description":"Factor XIIIa (FXIIIa) is a transglutaminase of major therapeutic interest for the development of anticoagulants due to its essential role in the blood coagulation cascade. While numerous FXIIIa inhibitors have been reported, they failed to reach clinical evaluation due to their lack of metabolic stability and low selectivity over transglutaminase 2 (TG2). Furthermore, the chemical tools available for the study of FXIIIa activity and localization are extremely limited. To combat these shortcomings, we designed, synthesised, and evaluated a library of 21 novel FXIIIa inhibitors. Electrophilic warheads, linker lengths, and hydrophobic units were varied on small molecule and peptidic scaffolds to optimize isozyme selectivity and potency. A previously reported FXIIIa inhibitor was then adapted ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-05-18T12:54:50.277Z","creation":"2025-04-03T22:08:29.094Z"},"accession":"S-EPMC9960274","cross_references":{"pubmed":["36838622"],"doi":["10.3390/molecules28041634"]}}